320 A&E patients die needlessly every week linked to hospital bed waits
Some 320 patients a week may have died needlessly in England last year due to very long waits in A&E for a hospital bed, figures suggest.
Calculations by the Royal College of Emergency Medicine (RCEM) estimate there were more than 16,600 deaths of patients linked to long waits for a bed, an increase of a fifth on 2023.
RCEM's president, Dr Adrian Boyle, said the figures were 'the equivalent of two aeroplanes crashing every week' and were devastating for families.
He said: 'I am at a loss as how to adequately describe the scale of this figure.
'To give it some context, it is the equivalent of two aeroplanes crashing every week.
'It's sobering, heartbreaking, devastating and more. Because this is so much more than just data and statistics.
'Each number represents a person – a dearly loved family member, grandparents, parents, siblings and friends – who has died because of a system in crisis.
'These were patients who were stuck in emergency departments, watching the clock tick by as they waited extremely long hours, often on a trolley in a corridor, for an in-patient bed to become available for them.'
Dr Boyle will discuss the findings at the launch of the newly formed All-Party Parliamentary Group (APPG) on Emergency Care.
The group, chaired by Labour MP Dr Rosena Allin-Khan, an A&E doctor, has said it will look first at the harm caused to patients by delays and 'corridor care'.
Last year, more than 1.7 million patients waited 12 hours or more to be admitted, discharged or transferred from A&E.
Of these, 69.2% were waiting to be admitted to a ward for further care, the RCEM said.
For its excess death estimates, the RCEM uses a study of more than five million NHS patients published in the Emergency Medicine Journal (EMJ) in 2021.
This found there was one excess death for every 72 patients that spent eight to 12 hours in an A&E department prior to being found a bed.
The risk of death started to increase after five hours and got worse with longer waiting times.
Using this method, RCEM estimates there were 16,644 excess deaths in 2024 related to stays of 12 hours or more.
This is the equivalent of 320 lives lost every week and up 20% on the 13, 919 the previous year.
Dr Boyle said the methodology only applies to one group of NHS patients and 'we know there may well be many more tragic deaths linked to long stays.'
He added: 'For example, patients left waiting for urgent medical care in the community because ambulances can't safely hand over their patients in emergency departments because they are full, or those too anxious to seek help with they should.
'The issue also affects A&E staff who are trying their best to deliver care in areas that are designed to be throughfares – not treatment spaces.
'Ultimately, the emergency care crisis is fixable. It's all about flow – getting patients into to a ward bed when they need one and home again as soon as they are well enough to leave.
'How best to do this, will be considered by the APPG and we look forward to working with the MPs and peers who have joined as members to resuscitate emergency care.'
Dr Boyle will tell the launch event that almost half a million (478,901) patients waited more than 24 hours in A&E last year – one in every 35 patients attending.
He will say this is 100,410 more people compared to 2023.
Dr Allin-Khan said: 'These statistics make for sobering reading. Ever-increasing numbers of excess deaths and long wait times in our emergency departments are simply not sustainable.
'As an emergency doctor, I know exactly how stretched our A&Es across the country are, as I see it on a weekly basis on my shifts.
'The Government have pledged to fix the foundations of our public services and our A&Es must be at the front and centre of this ambition.
'There has never been an APPG for Emergency Care before and this is exactly the vehicle needed to bring together industry experts, legislators and the Government to move things forward.
'I look forward to working with RCEM and the Government constructively to bring these numbers down, ensuring everyone receives the best quality care, with the dignity they deserve.'
Dr Nick Murch, president of the Society for Acute Medicine, said the figures represented a 'profound failure within our healthcare system', adding: 'It is simply shocking to see such a large number of deaths associated with excess waits in emergency departments, but, tragically, the warning signs have been present for far too long.
'We must ensure that 12-hour waits in emergency departments again become an infrequent exception rather than the norm and that will require urgent and adequate action on workforce and capacity issues which remain unresolved.'
A Department of Health and Social Care spokesperson said: 'This report lays bare the crisis in NHS waiting times we inherited, with patients suffering unacceptable delays for urgent treatment. It will be a long road to fix our NHS, but we are doing the work to get us there.
'It's why we are investing an extra £26 billion to reform the health service and make it fit for the future through our plan for change.
'This includes shifting services from hospital to community to ease pressure on A&E departments, on top of recruiting an extra 1,000 GPs to reach patients earlier and move towards prevention.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
2 hours ago
- Telegraph
NHS faces paying more for US drugs to avoid future Trump tariffs
Britain faces paying more for US drugs as part of a deal to avoid future tariffs from Donald Trump. The NHS will review drug pricing to take into account the 'concerns of the president', according to documents released after a trade agreement was signed earlier this year. White House sources said it expected the NHS to pay higher prices for American drugs in an attempt to boost the interests of corporate America. A Westminster source said: 'There's an understanding that we would look at the drug pricing issue in the concerns of the president.' The disclosure is likely to increase concerns about American interference in the British health service, which has long been regarded as a flashpoint in trade talks. It comes after Rachel Reeves announced a record £29 billion investment in the NHS in last week's spending review. The Chancellor's plans will drive spending on the health service up towards 50 per cent of all taxpayer expenditure by the mid-2030s, according to economists at the Resolution Foundation. The Telegraph has also learnt that under the terms of the trade deal with America, the UK has agreed to take fewer Chinese drugs, in a clause similar to the 'veto' given to Mr Trump over Chinese investment in Britain. The White House has asked the UK for assurances that steel and pharmaceutical products exported to the US do not originate in China, amid fears the deal could be used to 'circumvent' Mr Trump's punishing tariffs on Beijing. Mr Trump is enraged by how much more America pays for drugs compared with other countries and considers it to be the same issue as he has raised on defence spending. Just as the US president has heaped pressure on European nations to increase the GDP share they allocate to defence, he thinks they should spend more on drug development. An industry source said: 'The way we've been thinking about it and many in the administration have been thinking about it, it's more like the model in Nato, where countries contribute some share of their GDP.' Britain and the US 'intend to promptly negotiate significantly preferential treatment outcomes on pharmaceuticals and pharmaceutical ingredients', the trade deal reads. Pharmaceutical companies are also pushing for reductions in the revenue sales rebates they pay to the NHS under the voluntary scheme for branded medicines pricing, access and growth (VPAG) – a mechanism that the UK uses to make sure the NHS does not overpay. Non-US countries are 'free-riding' Last week, Albert Bourla, Pfizer's chief executive, said non-US countries were 'free-riding' and called for a US government-led push to make other nations increase their proportionate spend on innovative medicines. He said White House officials were discussing drug prices in trade negotiations with other countries. 'We represent in UK 0.3pc of their GDP per capita. That's how much they spend on medicine. So yes, they can increase prices,' Mr Bourla said. Industry sources said there was no indication yet on what the White House would consider to be a fair level of spending. Whatever the benchmark, Britain will face one of the biggest step-ups. UK expenditure on new innovative medicines is just 0.28pc of its GDP, roughly a third of America's proportionate spending of 0.78pc of its GDP. Even among other G7 nations, the UK is an anomaly. Germany spends 0.4pc of its GDP while Italy spends 0.5pc. Most large pharmaceutical companies generate between half and three quarters of their profits in the US, despite the fact that America typically makes up less than a fifth of their sales. This is because drug prices outside of the US can cost as little as 30pc of what Americans pay. Yet, pharmaceutical companies rely on higher US prices to fund drug research and development, which the rest of the world benefits from. A month ago, Mr Trump signed an executive order titled 'Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients', which hit out at 'global freeloading' on drug pricing. It stated that 'Americans should not be forced to subsidise low-cost prescription drugs and biologics in other developed countries, and face overcharges for the same products in the United States' and ordered his commerce secretary to 'consider all necessary action regarding the export of pharmaceutical drugs or precursor material that may be fuelling the global price discrimination'. Trung Huynh, the head of pharma analysis at UBS, said: 'The crux of this issue is Trump thinks that the US is subsidising the rest of the world with drug prices. 'The president has said he wants to equalise pricing between the US and ex-US. And the way he wants to do it is not necessarily to bring down US prices all the way to where ex-US prices are, but he wants to use trade and tariffs as a pressure point to get countries to increase their prices. 'If he can offset some of the price by increasing prices higher ex-US, then the prices in America don't have to go down so much.' Mr Huynh added: 'It's going to be very hard for him to do. Because [in the UK deal] it hinges on the NHS, which we know has got zero money.' Under VPAG, pharmaceutical companies hand back at least 23pc of their revenue from sales of branded medicines back to the NHS, worth £3bn in the past financial year. The industry is pushing for this clawback to be cut to 10pc, which would mean the NHS would have to spend around 1.54bn more on the same medicines on an annual basis. The Government has already committed to reviewing the scheme, a decision which is understood to pre-date US trade negotiations. A government spokesman said: 'This Government is clear that we will only ever sign trade agreements that align with the UK's national interests and to suggest otherwise would be misleading. 'The UK has well-established and effective mechanisms for managing the costs of medicines and has clear processes in place to mitigate risks to supply.'
The Guardian
2 hours ago
- The Guardian
My father died in a care home and all I got was denials and excuses
The situation at The Firs care home in Nottinghamshire, which was shut down in April, is dreadful for patients, families and staff ('How did it get to this?' What happens when care in a residential home breaks down, 7 June). But the Care Quality Commission (CQC) is not the only body to blame for failings like this. It can't investigate individual complaints – this is mostly down to the local government and social care ombudsman (LGSCO), but also the parliamentary and health service ombudsman (PHSO). It depends on who funds the care; in theory the same care home could be dealing with two ombudsman staff unaware of each other. Both are equally damned on Trustpilot with overwhelmingly negative reviews. My dad died two days after he had been moved to a home for palliative care. So much went wrong on that awful day, with staff who didn't care and with no involvement with any senior staff. I complained to the manager and then the company headquarters. I received many denials and excuses, one of which was so clearly untrue that I thought I'd caught them out. I told the PHSO everything. I waited for eight months, only to have every ridiculous excuse parroted back to me as a reason for not investigating. I don't believe the LGSCO would have been any better. The care home company knew I had complained and had time to prepare for an investigation, which never came. All I did by complaining was show what it could get away with. Other homes in the same organisation have been graded as inadequate or requiring improvement, with poor staffing levels and attitudes to patients especially marked. So criticise the CQC, but don't spare either and address supplied Your article made me cry. My parents (90 and 92) have, since February, suffered deterioration in their health such that both now need full-time care. Three of the four local-authority-provided 'rehab' places have so far been utterly woeful. The home that my father is currently living in is disastrous for a person in his position. My sister and I are desperately trying to sort an alternative for him, but it takes time and every day he is there is a day too long. And as for whistleblowing, we tried that when a carer was verbally abusive to my mother. The difficulties we are having moving her because of her record of 'very difficult behaviour' are not and address supplied
Daily Mail
2 hours ago
- Daily Mail
Lucy Letby supporter claims neo-natal unit where baby serial killer worked was 'not fit for purpose'
The Countess of Chester Hospital's neo-natal unit was 'not fit for purpose' before Lucy Letby started murdering babies, a former nurse who worked there has claimed. Michele Worden said redundancies led to a loss of senior staff and plumbing issues created a 'perfect storm' for care failings. The former advanced nurse practitioner left the Countess after being made redundant in 2007, four years before Letby started working and eight years before her killing spree began. She told the Nursing Times that when the unit was downgraded in around 2006 and stopped caring for very premature babies under 27 weeks, senior nurses were replaced with junior staff who were asked to care for infants 'above their capabilities [and] training.' She said: 'It wasn't just the neonatal unit that wasn't fit for purpose, the whole maternity and paediatric and gynaecology… was not fit for purpose. 'The problems with the sewage and blocked sinks were not just [on] the neonatal unit, it was on the labour ward, it was all over.' Ms Worden said she believed the situation at the Countess of Chester was 'no different' to other NHS hospitals where maternity scandals have been uncovered in recent years. 'Hopefully Lucy will be exonerated,' she said. 'Chester is no different than Shrewsbury, Nottingham, Morecambe Bay. Women and children's healthcare has never been a high priority.' Letby, 38, is serving 15 whole life terms after being convicted of the murder of seven babies and attempted murder of seven more, including one baby girl she tried to kill twice. Plumber Lorenzo Mansutti, estates manager at the Countess, was the only witness called by Letby in her defence at her Manchester Crown Court trial. He admitted drainage problems were a 'weekly' issue at the hospital's 50-year-old Women's and Children's Building and told the jury that he remembered an incident when raw sewage backed up into sinks in the intensive care nursery. But he said it was a 'one off' and insisted that at no point were staff unable to wash their hands because the hospital had 'backup' portable handwashing units on site. The problem was not logged as a formal incident, so no exact date for the incident could be found. Letby's trial heard that none of the seven babies who died collapsed due to a bacterial infection associated with poor sewage. Cheshire police are continuing to investigate the former nurse and last year confirmed they had questioned her in prison in connection with more baby deaths. But, following a presentation from 14 international experts in February, who claim none of the babies were murdered but died due to poor care, there has been a continued chorus of people questioning the safety of her convictions. Letby has twice applied and been refused leave to appeal, but her new legal team have submitted a file of evidence to the Criminal Cases Review Commission, the body that investigates potential miscarriages of justice, in a last ditch attempt to get her convictions overturned. They claim the testimony of lead prosecution expert Dewi Evans was biased and that he changed his mind over the method of murder of one of the children murdered by Letby, a boy known as Baby C. Dr Evans has denied this and the Court of Appeal has already dismissed claims he was not suitably qualified or lacked independence. Yesterday it emerged that Dr Evans, who has been subjected to intense trolling online from Letby supporters, had been involved in an online row with one of them - an anonymous statistician who Dr Evans accused of being motivated by a sexual attraction to Letby. According to the statistician, Dr Evans wrote: 'You seem very intense, and it's not unusual for men to have the hots for pretty young blonde females. A nursing uniform is a turn-on for some by all accounts. 'I would suggest you need to get out more, find yourself an available pretty young blonde female, with/without nursing credentials. But one who doesn't go to work intent on murdering her patients.' The statistician said it was 'absurd' to say he believed Letby was innocent because she was 'blonde and pretty' and insisted he had come to that view after reviewing the transcripts of the trial.
